Search

SPRINGFIELD, N.J.: Evergreen Theragnostics, Inc. has issued the following news release: Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients, is pleased to [...]

Several new studies in lung cancer have recently opened for enrollment. One study is assessing whether an investigational drug called V940, when added to pembrolizumab, delays cancer recurrence better than pembrolizumab alone in patients with resected stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC). Another study is investigating whether an experimental antibody-drug conjugate called MK-2870, when added to pembrolizumab, prolongs survival in patients with metastatic NSCLC. A third study is examining whether an experimental oral KRAS G12C inhibitor called LY3537982 enhances the effectiveness of standard treatment in patients with untreated locally advanced or metastatic NSCLC with KRAS G12C mutations. Other studies are exploring treatments for NSCLC with HER2 mutations and PD-L1-positive NSCLC. [Extracted from the article]

2024 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on non-small cell lung cancer have been published. According to news reporting [...]

M2 PHARMA-September 9, 2024-Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024 (C)2024 M2 COMMUNICATIONS Biotechnology company Amgen Inc (NASDAQ: AMGN) announced on Monday that [...]

M2 EQUITYBITES-September 9, 2024-Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024 (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biotechnology company Amgen Inc (NASDAQ: AMGN) announced on Monday [...]

Cambridge, United Kingdom: AstraZeneca has issued the following press release: High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) [...]

(7) Merck & Co.'s Keytruda wins FDA approval for bladdercancer, but misses key mark in small cell lung cancer trial. This was helped by the firstRNAi drug therapy, patisiran, gaining EU and US market approval in 2018.One example of big pharma entering the field is Novartis AG (Basel CHE),which recently announced that it would spend €8.8B to acquire TheMedicines Company along with its experimental RNAi drug inclisiran forthe treatment of cardiovascular disease. (13) NORTHSEA THERAPEUTICS BV (Naarden NLD) has raised a €36M($40M) Series B round to fund the end of a Phase 2b trial of its leadfatty acid drug to treat the liver condition NASH, as well asadvancing two other drugs to clinical trials. And the FDA may have rebuffedAstraZeneca PLC (London) in its pursuit to expand the approval ofits SGLT2 diabetes drug to type 1 patients, but regulators are nowpaving the way for another big add-on in approvals. [Extracted from the article]

Merck has announced its plans to acquire Harpoon Therapeutics, a clinical-stage immunotherapy company, for approximately $680 million. The deal involves Merck paying $23 per share in cash, more than double Harpoon's closing price on Friday. The acquisition will add Harpoon's HPN328, currently being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors, to Merck's portfolio. The transaction is expected to be completed in the first half of the year and will result in a charge of about $650 million for Merck. Harpoon's shares have risen by approximately 110% in premarket trading. [Extracted from the article]

The article offers news briefs related to pharmaceutical industry. Topics discussed include treatment of advanced form of lung cancer with a drug from Amgen Inc., small-cell lung cancer patients are receiving PD-L1 Imfinzi from AstraZeneca PLC, and Sanofi SA has spent 300 million dollar in cash to get into a 1.7 billion dollar alliance with Lexicon Pharmaceuticals Inc.

09/09 (7) AstraZeneca's SGLT2 med Farxiga outflanks competitors with26% lower CV risk. AstraZeneca PLC's (London) diabetes med Farxiga is stilllooking for the cardiovascular label updates its sodium-glucosecotransporter-2 (SGLT2) competitors already tout. The first two gene therapies to be included inCigna's program are blindness therapy, Luxturna, and the most expensivedrug in the world, Novartis AG's (Basel CHE) $2.1 million spinalmuscular atrophy treatment, Zolgensma, the insurer said. Novartis is aiming to win approval for oralcapmatinib as a first-line treatment for patients with metastatic METexon14 skipping-mutated non-small cell lung cancer (NSCLC), a form ofthe disease for which there are no targeted therapies now, the Swiss-basedcompany said on Friday. [Extracted from the article]

Byline: Linda Lindner East Hanover-based Novartis said Wednesday that the U.S. Food and Drug Administration (FDA) approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic [...]

Byline: Mass. Lawyers Weekly Staff The plaintiff's decedent died at age 66 from metastatic non-small cell lung cancer. The decedent's medical history included obesity, spinal stenosis, arthritis, asthma, COPD, spine [...]

There are usually no signs in the early stages, but when people eventually develop symptoms, one of the most recognized signs is a persistent cough. Coughing up blood and pain [...]

Byline: Daily Record Staff A Rockville maker of a cancer diagnostics system has received a two-year, $1.5 millioncontract to continue development of its immunotherapy test. BioMarker Strategies LLC received the [...]

BOSTON: Verastem, Inc. has issued the following news release: Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today [...]

London, Britain: AstraZeneca has issued the following press release: AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for an additional dosing option, 1,500mg fixed [...]

Verastem Oncology, Inc. (Nasdaq:VSTM) , a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, [...]

M2 PRESSWIRE-December 15, 2020-: Imfinzi recommended for approval in the EU by CHMP for less-frequent, fixed-dose use in unresectable non-small cell lung cancer (C)1994-2020 M2 COMMUNICATIONS RDATE:15122020 * Option would [...]

(GlobeNewswire) - Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor [...]

Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has [...]

Acclaim-1 trial combines REQORSA[TM] immunogene therapy drug with AstraZeneca's Tagrisso[R] Company expects to recruit approximately 10 sites across the United States AUSTIN, Texas -- Genprex, Inc. ('Genprex' or the 'Company') [...]

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping KEYNOTE-598, a Phase 3 trial investigating KEYTRUDA, Mercks anti-PD-1 therapy, in [...]

(GlobeNewswire) - Kitov Pharma Ltd. (Kitov) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the company and Bristol Myers [...]

TEL AVIV, Israel, Nov 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Kitov Pharma Ltd. ('Kitov') (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug [...]

BEIJING, China -- The following information was released by the Chinese Academy of Sciences: Recently, a research team led by Prof. LIN Wenchu from the High Magnetic Field Laboratory of [...]

CAMBRIDGE: Foundation Medicine has issued the following press release: -Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne(r)Liquid CDx for three new companion diagnostic [...]

Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOneLiquid CDx for three new companion diagnostic indications to help match patients who may benefit from [...]

BRIDGEWATER: Hillstream BioPharma has issued the following news release: Hillstream BioPharma Inc. ('Hillstream', the 'Company'), a clinical-stage pharmaceutical company, announced that it has successfully completed a pre-Investigational New Drug (IND) [...]

(GlobeNewswire) - Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in [...]

ROCKVILLE, Md.: NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it has entered into a second clinical trial collaboration agreement with F. Hoffmann-La Roche (Roche) to evaluate [...]

MALVERN, Pa., Oct 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics [...]

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it has entered into a second clinical trial collaboration agreement with F. Hoffmann-La Roche (Roche) to evaluate the combination [...]

ROCKVILLE, Md. -- NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it has entered into a second clinical trial collaboration agreement with F. Hoffmann-La Roche (Roche) to [...]

Amsterdam: OSE IMMUNE has issued the following news release: OSE Immunotherapeutics SA (Paris: OSE) (ISIN: FR0012127173; Mnemo: OSE), presented the positive results of step 1 of phase 3 of the [...]

Belgium: Janssen has issued the following news release: FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday [...]

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor [...]

CAMBRIDGE, Mass. & BEIJING -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from [...]

Waltham: Thermo Fisher Scientific, Inc. (TMO) has issued the following press release: The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target [...]

CAMBRIDGE: Sanofi has issued the following news release: Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will present new, positive data for PD-1 inhibitor Libtayo(r) (cemiplimab) at the European Society for [...]

Dublin, Sep 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2020' report has been added to ResearchAndMarkets.com's offering. The report [...]

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed [...]

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a [...]

TOKYO: Daiichi Sankyo Company, Limited has issued the following press release: -Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca [...]

TOKYO & BASKING RIDGE, N.J. & MUNICH -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to [...]

NANTES, France, Jul 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Step-1 results of its Phase 3 clinical trial of investigational product [...]

(GlobeNewswire) - AnHeart Therapeutics, Co., Ltd. (AnHeart), a clinical stage oncology company focused on underserved patients in global markets, today announced that the first patient has been dosed with taletrectinib [...]

SHANGHAI, China and NEW YORK, Jul 21, 2020 (GLOBE NEWSWIRE via COMTEX) -- AnHeart Therapeutics, Co., Ltd. ('AnHeart'), a clinical stage oncology company focused on underserved patients in global markets, [...]

Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase [...]

Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib Participation will provide Ipsen access to the respective study results to support potential future regulatory submissions [...]